Bio-Rad Laboratories, Inc. reports news on its life science research and clinical diagnostics products, including instruments, reagents, test systems, specialized quality controls, blood typing, diabetes products, infectious disease products, and Droplet Digital PCR technologies.
Company updates commonly cover quarterly and annual financial results, Clinical Diagnostics and Life Science segment trends, currency and end-market conditions, product portfolio developments, share repurchases, earnings calls, and healthcare investor conferences. Bio-Rad’s customer base includes universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its third-quarter 2022 financial results on October 27, 2022, after market close. A conference call discussing these results is scheduled for 2 PM Pacific Time the same day. Bio-Rad, a leader in life science research and clinical diagnostics, generated $2.9 billion in revenues for 2021 and employs approximately 7,900 individuals worldwide. Investors can access a live webcast via the 'Investor Relations' section of the company's website.
Bio-Rad Laboratories (NYSE: BIO) has announced the acquisition of Curiosity Diagnostics for up to $170 million, comprising $100 million in cash and $70 million in future milestones. Curiosity, based in Poland, is developing a rapid diagnostics PCR system for the molecular diagnostics market. This acquisition aims to enhance Bio-Rad's Clinical Diagnostics Group, expanding into near-patient molecular diagnostics. With Bio-Rad's extensive market presence and Curiosity's innovative technology, the deal is anticipated to improve product offerings and market reach.
Bio-Rad Laboratories (NYSE: BIO, BIO.B) reported Q2 2022 net sales of $691.1 million, down 3.5% year-over-year, with COVID-related revenue falling to approximately $33 million. Currency-neutral sales recorded a 0.5% increase. Life Science segment sales decreased by 3.5% to $322.4 million, while Clinical Diagnostics fell 3.3% to $367.8 million. A significant net loss of $927.2 million was reported versus a net income of $914.1 million in Q2 2021, largely due to equity securities valuation changes. The full-year outlook remains positive with expected revenue growth and an increased share repurchase program of $200 million.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its financial results for Q2 2022 on July 28, 2022, after market close. A conference call is scheduled for 3 PM Pacific Time (6 PM Eastern Time) to discuss these results. Investors can participate by calling 844-200-6205 within the U.S. or +1 929-526-1599 internationally, access code: 715914. A live webcast will also be available.
Summary not available.
Bio-Rad Laboratories, Inc. reported Q1 2022 net sales of $700.1 million, down 3.7% from Q1 2021. Excluding COVID-related sales, revenue increased 6.5% on a currency-neutral basis, driven by strong growth in Process Media and Droplet Digital PCR products. The net loss for the quarter was $3.37 billion or $112.57 per share, significantly impacted by changes in the fair market value of equity securities. Non-GAAP net income was $149.1 million, or $4.94 per diluted share. The company anticipates 1.0% to 2.0% revenue growth for FY 2022.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for Q1 2022 on April 28, 2022, after the market closes. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). The company, a leader in life science research and clinical diagnostics, had revenues of $2.9 billion in 2021 and has been operational since 1952, serving a global customer base focused on advancing healthcare.
Bio-Rad Laboratories, Inc. (NYSE: BIO) has successfully closed an underwritten public offering of $1.2 billion in aggregate principal amount of notes. The offering consists of $400 million due in 2027 and $800 million due in 2032, with interest rates of 3.300% and 3.700%, respectively. The proceeds will be used for general corporate purposes, including working capital and potential acquisitions. Major banks such as Citigroup, Goldman Sachs, and J.P. Morgan managed the offering. Bio-Rad reported revenues of $2.9 billion in 2021.
Bio-Rad Laboratories, Inc. (NYSE: BIO) is hosting an investor day in New York City, highlighting its growth strategy and financial targets. The company aims for a 9% core revenue CAGR from 2021 to 2025 and a 28% adjusted EBITDA margin by 2025. Bio-Rad emphasizes portfolio transformation and expansion in the biopharma sector. The Life Science Research and Clinical Diagnostics segments are expected to drive growth through advanced products and solutions. Bio-Rad has consistently exceeded its previous financial targets, setting a positive outlook for future performance.
Bio-Rad Laboratories reported Q4 2021 net sales of $732.8 million, down 7.2% year-over-year, with a gross margin of 54.7%. The Life Science segment saw a 23.8% sales decline primarily due to reduced COVID-19 demand, while Clinical Diagnostics rose by 12.6%. The company experienced a net loss of $1,573.7 million or $52.59 per diluted share, impacted by equity securities valuation changes. For full-year 2021, net sales increased 14.8% to $2.92 billion with a net income of $4.24 billion.